<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim oof this study was to investigate the immunohistochemical expression of p53, mdm2, and waf1/p21 proteins in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), <z:hpo ids='HP_0011009'>acute</z:hpo> myelogenous <z:mpath ids='MPATH_336'>leukaemias</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Paraffin-sections of bone marrow biopsies from 30 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (6 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>) 22 AML (4 cases occurring in the setting of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), 16 <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e>), and 10 cases without alterations were investigated by immunohistochemistry for p53, waf1/p21, mdm2 and Ki67 proteins </plain></SENT>
<SENT sid="2" pm="."><plain>P53 was detected in immature myeloid cells in 6/30 MDS (20%) and in 6/22 AML (27%) while it was not expressed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Of the 6 p53 positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 3 occurred as evolution of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and 3 were de novo <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemias</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>Waf1/p21 was detected in 5/22 (23%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in immature myeloid cells </plain></SENT>
<SENT sid="5" pm="."><plain>Waf1/p21 was also expressed in 18/30 (60%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and 10/16 (63%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> in variable proportion (5-25%) of the mature myeloid cells and megakaryocytes </plain></SENT>
<SENT sid="6" pm="."><plain>Waf1/p21 was not detected in immature myeloid cells in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Mdm2 protein was expressed in 3/30 (10%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in the immature myeloid cells and in 1/22 AML in blastic cells </plain></SENT>
<SENT sid="8" pm="."><plain>The combined immunophenotypes of immature myeloid cells of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were: p53+/mdm2+/waf1-: 3, p53+/mdm2-/waf1-: 3, while the immunohistochemical patterns of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> were: p53+/mdm2-/waf1-: 4, p53+/mdm2+/waf1+: 1, p53+/mdm2-/waf1+: 1, p53-/mdm2-/waf1+: 3 </plain></SENT>
<SENT sid="9" pm="."><plain>Ki67/MIB1 staining was found in at least 30% of immature myeloid cells in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and in at least 20% of these cells in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, our results indicate that p53 protein is overexpressed in the myeloid lineage in a proportion of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, while is not detected in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> and <z:mpath ids='MPATH_458'>normal</z:mpath> bone marrow, p53 expression was much more frequent in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> occurring as an evolution of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> than in de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>The combined immunophenotypes of p53 positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> suggest that p53 overexpression may be due to mutation, in some <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases with the p53+/mdm2-/waf1- phenotype </plain></SENT>
<SENT sid="12" pm="."><plain>However, it would be also possible that p53 protein accumulation is not related to p53 mutation but to inhibition of p53/mdm2 binding due to mdm2 defects and/or other events related to cell stress signals </plain></SENT>
<SENT sid="13" pm="."><plain>On the other hand, waf1/p21 protein overexpression without p53 expression in some <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> could be p53-independent and may represent an attempt to control the high proliferation rate which was evidenced by Ki67/MIB1 immunostaining </plain></SENT>
<SENT sid="14" pm="."><plain>However, the possibility of p21 to arrest cell-cycle, in these cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, seems to be overridden, suggesting that cell-cycle deregulation may be involved in a proportion of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>